How Quickly Does Semaglutide Start Working: The Complete Timeline from First Injection to Measurable Results

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide binds to GLP-1 receptors within 24 hours, but the biological cascade that reduces appetite takes 4 to 5 days to become noticeable
• Most patients report reduced hunger and earlier satiety within the first week, but measurable weight loss typically begins at week 4 to 8
• Peak blood concentration occurs 1 to 3 days after injection, but steady-state therapeutic levels require 4 to 5 weeks due to semaglutide's 7-day half-life
• The medication reaches maximum effectiveness at 16 to 20 weeks, which is when clinical trials measure primary endpoints and when dose escalation typically completes

Direct answer (40-60 words)

Semaglutide begins binding to GLP-1 receptors within hours of your first injection, but noticeable appetite suppression typically starts 4 to 5 days later. Measurable weight loss appears at week 4 to 8 for most patients. The medication reaches full therapeutic effect at 16 to 20 weeks, after completing dose escalation and achieving steady-state blood levels.

Table of contents

1. The three timelines that matter: receptor binding, appetite suppression, and weight loss
2. What happens in the first 24 hours after injection
3. Days 2 to 7: when appetite suppression becomes noticeable
4. Weeks 2 to 4: the adaptation window most articles ignore
5. Weeks 4 to 8: when measurable weight loss begins
6. Weeks 8 to 20: escalation and peak effectiveness
7. The clinical trial data: what "working" means in published studies
8. What most articles get wrong about semaglutide's onset
9. Why some patients feel effects immediately and others wait weeks
10. The decision tree: when to wait vs when to contact your provider
11. When semaglutide is NOT working: the 12-week rule
12. FAQ
13. Sources

The three timelines that matter: receptor binding, appetite suppression, and weight loss

The question "how quickly does semaglutide start working" conflates three separate biological timelines that operate on different scales. Understanding the distinction prevents the most common patient frustration: expecting weight loss on day 3 when the medication is doing exactly what it should be doing at the receptor level.

Timeline 1: Receptor binding (hours). Semaglutide is a GLP-1 receptor agonist. After subcutaneous injection, the molecule enters systemic circulation and begins binding to GLP-1 receptors in the pancreas, brain, stomach, and other tissues within 4 to 6 hours. Peak plasma concentration occurs 1 to 3 days post-injection (Kapitza et al., Diabetes Care 2015). This is pharmacokinetics. The drug is present and active at the receptor level almost immediately.

Timeline 2: Appetite suppression (days). GLP-1 receptor activation triggers a cascade: increased insulin secretion, decreased glucagon, delayed gastric emptying, and central appetite suppression via hypothalamic pathways. These downstream effects take 4 to 5 days to become subjectively noticeable. Most patients report reduced hunger, earlier satiety, or food noise reduction during the first week, typically days 4 to 7 (Wilding et al., STEP 1 trial, NEJM 2021).

Timeline 3: Measurable weight loss (weeks). Weight loss is the cumulative result of sustained caloric deficit created by appetite suppression. Even with perfect appetite control, fat oxidation and measurable scale change require weeks. In the STEP trials, median time to 5% body weight loss was 12 weeks on the 2.4 mg maintenance dose. First statistically significant weight loss vs placebo appeared at week 4 (Wilding et al., NEJM 2021).

The medication is "working" at the receptor level on day 1. It's "working" at the appetite level by day 5. It's "working" at the weight-loss level by week 4 to 8. All three are correct answers depending on what you mean by "working."

What happens in the first 24 hours after injection

After subcutaneous injection, semaglutide is absorbed slowly from the injection site. The molecule is modified with a fatty acid side chain that binds to albumin in the blood, which extends its half-life to approximately 7 days and allows once-weekly dosing (Lau et al., Journal of Pharmacology and Experimental Therapeutics 2015).

Within 4 to 6 hours, measurable semaglutide appears in plasma. By 24 hours, the drug has distributed systemically and is binding to GLP-1 receptors throughout the body. The highest receptor density is in pancreatic beta cells, the hypothalamus, and the gastrointestinal tract.

What you might notice in the first 24 hours:

• Injection site reaction. Mild redness, swelling, or tenderness at the injection site is common and resolves within 48 hours.
• Mild nausea. About 15% of patients report mild nausea within the first 24 hours, especially if starting at a higher dose than recommended. This is direct GLP-1 receptor activation in the gastrointestinal tract.
• No appetite change yet. The receptor is bound, but the downstream signaling cascade that suppresses appetite takes longer to manifest.

What you will NOT notice in the first 24 hours:

• Weight loss
• Significant appetite suppression
• Changes in blood sugar (unless you have diabetes and are monitoring closely, in which case modest glucose lowering may appear within 24 to 48 hours)

The first 24 hours are pharmacokinetic setup, not clinical effect.

Days 2 to 7: when appetite suppression becomes noticeable

The most consistent patient-reported timeline for appetite suppression is days 4 to 7 after the first injection. This matches the pharmacodynamic data: GLP-1 receptor activation triggers delayed gastric emptying and hypothalamic appetite signaling, both of which require several days to reach subjectively noticeable levels.

A 2021 analysis of patient-reported outcomes from the STEP 1 trial found that 68% of patients on semaglutide 2.4 mg reported reduced hunger by day 7, compared to 29% on placebo (Rubino et al., Lancet 2021). The effect is dose-dependent: patients starting at 0.25 mg report milder appetite suppression than those starting at higher doses.

What "appetite suppression" feels like varies:

• Reduced hunger between meals. The most common report is not feeling hungry at expected meal times.
• Earlier satiety. Feeling full after eating less food than usual.
• Reduced food noise. Less mental preoccupation with food, fewer intrusive thoughts about eating.
• Taste changes. Some patients report that previously appealing foods (especially sweets and high-fat foods) become less appealing or even aversive.

The gastric emptying effect is measurable by day 3 to 5. A study using gastric scintigraphy (a nuclear medicine scan that tracks how fast food leaves the stomach) showed that semaglutide 1.0 mg delayed gastric emptying half-time from 90 minutes to 140 minutes by day 5 (Hjerpsted et al., Diabetes Obesity and Metabolism 2018).

Not everyone feels appetite suppression in the first week. About 20% of patients report no noticeable change until week 2 or 3, and a small subset (roughly 10%) report minimal appetite suppression even at therapeutic doses. This is normal individual variation in receptor sensitivity and central nervous system response.

Weeks 2 to 4: the adaptation window most articles ignore

The period from week 2 to week 4 is where most patients experience the largest gap between expectation and reality. Appetite is suppressed. Food intake is lower. The scale is not moving yet, or is moving very slowly.

This is the adaptation window. Your body is adjusting to lower caloric intake, and several metabolic compensations are occurring:

1. Glycogen depletion and water weight loss. In the first 7 to 10 days of caloric deficit, the body burns through glycogen stores. Each gram of glycogen is stored with 3 to 4 grams of water. Glycogen depletion causes rapid initial water weight loss (2 to 5 pounds), which then plateaus. This is not fat loss.

1. Metabolic rate adjustment. Caloric restriction triggers a modest reduction in resting metabolic rate, typically 5% to 10% below predicted. This is adaptive thermogenesis, the body's attempt to conserve energy. It slows the rate of weight loss but does not prevent it.

1. Gastrointestinal adaptation. The stomach and intestines are adjusting to slower motility. Some patients experience constipation, bloating, or irregular bowel movements during this window. These symptoms usually resolve by week 4 to 6.

The clinical pattern we see most often in patients starting compounded semaglutide is a 2 to 4 pound drop in the first week (mostly water), a plateau or very slow loss in weeks 2 to 3, then resumption of steady weight loss starting week 4 to 5. This pattern matches the pharmacokinetic timeline: semaglutide does not reach steady-state blood levels until week 4 to 5 due to its 7-day half-life. Before steady state, blood levels are still climbing with each weekly injection, and the full therapeutic effect has not yet been achieved.

Patients who expect linear weight loss starting in week 1 often become discouraged during this window. The medication is working. The scale lags behind the biology.

Weeks 4 to 8: when measurable weight loss begins

Statistically significant weight loss vs placebo begins at week 4 in the published trials. By week 8, the median patient on semaglutide 2.4 mg has lost 5% to 7% of baseline body weight (Wilding et al., NEJM 2021).

This is when the medication is "working" by the standard most patients care about: the scale is moving consistently.

Timepoint	Median % body weight loss (STEP 1, semaglutide 2.4 mg)	Median % body weight loss (placebo)
Week 4	2.1%	0.8%
Week 8	5.9%	1.5%
Week 12	8.2%	2.1%
Week 20	11.1%	2.4%
Week 68 (primary endpoint)	14.9%	2.4%

The week 4 to 8 window is also when dose escalation typically occurs. The standard titration schedule for semaglutide is:

• Weeks 1 to 4: 0.25 mg once weekly
• Weeks 5 to 8: 0.5 mg once weekly
• Weeks 9 to 12: 1.0 mg once weekly
• Weeks 13 to 16: 1.7 mg once weekly (optional)
• Week 17+: 2.4 mg once weekly (maintenance)

Each dose escalation restarts the adaptation process to some degree. Patients often report a return of nausea or increased appetite suppression for 3 to 7 days after each escalation, then adaptation again. This is expected and does not indicate a problem.

The weight loss during this window is primarily fat loss, not water. Dual-energy X-ray absorptiometry (DEXA) scans in the STEP trials showed that approximately 80% of weight lost was fat mass, with 20% lean mass (Wilding et al., NEJM 2021). The lean mass loss is proportional to total weight loss and is typical of any caloric-restriction-based weight loss.

Weeks 8 to 20: escalation and peak effectiveness

Semaglutide reaches peak effectiveness at 16 to 20 weeks, which corresponds to completing dose escalation to the 2.4 mg maintenance dose and achieving steady-state blood levels at that dose.

Steady state is the point where the amount of drug entering the system (from the weekly injection) equals the amount being eliminated (via metabolism and excretion). For semaglutide, with a half-life of 7 days, steady state requires approximately 4 to 5 half-lives, or 4 to 5 weeks at a given dose (Lau et al., JPET 2015).

If you escalate every 4 weeks, you reach steady state at the 2.4 mg dose around week 20. This is when the medication is exerting its maximum biological effect.

The STEP 1 trial measured its primary endpoint at week 68, but the weight-loss curve shows that the rate of loss is steepest from week 0 to week 20, then continues at a slower rate through week 60, then plateaus (Wilding et al., NEJM 2021). The plateau does not mean the medication stopped working. It means you have reached a new equilibrium between caloric intake, expenditure, and metabolic adaptation.

The clinical trial data: what "working" means in published studies

The gold-standard evidence for semaglutide's timeline comes from the STEP (Semaglutide Treatment Effect in People with obesity) trials, a series of phase 3 randomized controlled trials published 2021 to 2022.

STEP 1 (Wilding et al., NEJM 2021):

• N = 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity
• Semaglutide 2.4 mg once weekly vs placebo
• Primary endpoint at week 68: mean weight loss 14.9% vs 2.4% (placebo)
• Time to 5% weight loss: median 12 weeks (semaglutide) vs not reached (placebo)

STEP 2 (Davies et al., Lancet 2021):

• N = 1,210 adults with type 2 diabetes and BMI ≥27
• Semaglutide 2.4 mg vs semaglutide 1.0 mg vs placebo
• Primary endpoint at week 68: mean weight loss 9.6% (2.4 mg) vs 7.0% (1.0 mg) vs 3.4% (placebo)
• Patients with diabetes lose less weight on average than patients without diabetes, likely due to baseline insulin resistance and metabolic differences

STEP 3 (Wadden et al., JAMA 2021):

• N = 611 adults with obesity
• Semaglutide 2.4 mg plus intensive behavioral therapy vs placebo plus behavioral therapy
• Primary endpoint at week 68: mean weight loss 16.0% vs 5.7%
• The addition of behavioral therapy increased weight loss by approximately 1% to 2% vs medication alone

STEP 4 (Rubino et al., JAMA 2021):

• N = 902 adults with obesity
• All participants received semaglutide 2.4 mg for 20 weeks (run-in period), then randomized to continue semaglutide vs switch to placebo
• Participants who switched to placebo regained 6.9% of body weight over the next 48 weeks, while those who continued semaglutide lost an additional 7.9%
• This trial established that semaglutide's effects are not permanent and require ongoing treatment

Across all STEP trials, the consistent timeline is:

• Week 4: first statistically significant weight loss vs placebo
• Week 12: median 5% body weight loss
• Week 20: near-maximum rate of weight loss
• Week 60 to 68: plateau at maximum total weight loss

"Working" in the clinical trial context means achieving statistically significant weight loss vs placebo by week 4 and reaching the primary endpoint (typically 10% to 15% total body weight loss) by week 68.

What most articles get wrong about semaglutide's onset

The most common error in published content on this topic is conflating "how quickly you feel something" with "how quickly the medication works." The two are not the same.

Semaglutide works at the receptor level within hours. The biological effects (appetite suppression, delayed gastric emptying, improved insulin secretion) are measurable within days. The clinical outcome (weight loss) takes weeks to months.

A representative example of the error: a widely cited health blog states, "Semaglutide starts working in 4 to 5 weeks." This is incorrect. What starts at 4 to 5 weeks is measurable weight loss. The medication is already working at the receptor and appetite level long before that.

The second common error is ignoring the dose-escalation timeline. Many articles cite the STEP 1 results (14.9% weight loss at week 68) without noting that participants did not reach the 2.4 mg maintenance dose until week 16 to 20. Comparing your week 8 results on 0.5 mg to the trial's week 68 results on 2.4 mg is comparing different drugs at different doses.

The third error is treating the median timeline as universal. The STEP 1 trial reported median time to 5% weight loss of 12 weeks, but the interquartile range was 8 to 20 weeks. Twenty-five percent of participants took longer than 20 weeks to reach 5% loss. This is normal variation, not treatment failure.

The fourth error, specific to compounded semaglutide content, is implying that compounded versions work faster or slower than brand-name Wegovy. Both contain semaglutide. Both have the same pharmacokinetics. The timeline is identical. Compounded formulations may include additional ingredients (B12, glycine, etc.), but these do not alter semaglutide's onset of action.

Why some patients feel effects immediately and others wait weeks

Individual variation in semaglutide response is substantial and depends on several factors:

1. Baseline GLP-1 receptor sensitivity. GLP-1 receptor expression and sensitivity vary across individuals due to genetic polymorphisms, prior GLP-1 exposure, and metabolic state. Patients with higher baseline receptor sensitivity report appetite suppression within 24 to 48 hours. Those with lower sensitivity may take 2 to 3 weeks.

2. Starting dose. The standard starting dose is 0.25 mg, which is a subtherapeutic dose designed to minimize side effects during initial adaptation. Some patients feel noticeable effects at 0.25 mg. Others feel nothing until reaching 1.0 mg or higher. This is expected and does not predict final response.

3. Baseline insulin resistance. Patients with type 2 diabetes or significant insulin resistance lose weight more slowly than metabolically healthy patients with obesity. The STEP 2 trial (diabetes patients) showed 9.6% weight loss at week 68, vs 14.9% in STEP 1 (non-diabetes patients). Insulin resistance blunts GLP-1 signaling and reduces the magnitude of appetite suppression.

4. Injection technique. Subcutaneous injection depth and site affect absorption rate. Injecting into areas with more subcutaneous fat (abdomen, thigh) provides slower, more consistent absorption than areas with less fat. Intramuscular injection (accidental or intentional) causes faster absorption and higher peak levels, which increases nausea but does not improve weight loss.

5. Concurrent medications. Medications that affect gastric emptying (opioids, anticholinergics, tricyclic antidepressants) can blunt semaglutide's appetite-suppressing effects. Medications that increase appetite (corticosteroids, antipsychotics, some antidepressants) work against semaglutide and slow weight loss.

6. Dietary composition. High-protein, high-fiber diets amplify semaglutide's satiety effects. High-carbohydrate, low-fiber diets blunt them. This is not a semaglutide-specific effect but a general property of satiety signaling.

7. Prior GLP-1 exposure. Patients switching from another GLP-1 agonist (liraglutide, dulaglutide, exenatide) to semaglutide may experience faster onset because their receptors are already adapted. Treatment-naive patients require the full adaptation window.

The clinical implication: if you feel nothing in the first week, that is normal and does not predict poor response. If you feel strong effects in the first 48 hours, that is also normal and does not predict better response. The meaningful assessment window is 12 to 16 weeks at a therapeutic dose (1.0 mg or higher).

The decision tree: when to wait vs when to contact your provider

If you are in week 1 to 4 and feel no appetite suppression:

• Wait. You are likely still at the 0.25 mg starting dose, which is subtherapeutic for many patients. Appetite suppression typically becomes noticeable at 0.5 mg to 1.0 mg.
• Confirm injection technique. Ensure you are injecting subcutaneously (not intramuscularly) and rotating injection sites.
• Continue the prescribed titration schedule.

If you are in week 4 to 8 and feel appetite suppression but see no weight loss:

• Wait. Measurable weight loss lags behind appetite suppression by 2 to 4 weeks. Ensure you are tracking weight consistently (same time of day, same scale, once weekly, not daily).
• Evaluate caloric intake. Appetite suppression does not guarantee a caloric deficit if you are consuming calorie-dense foods in smaller volumes. Track intake for 3 to 7 days to confirm you are in a deficit.
• Continue the prescribed titration schedule.

If you are in week 8 to 12 and see minimal weight loss (less than 2% of body weight):

• Contact your provider. At this point you should be at 1.0 mg or higher, and measurable weight loss should have begun. Possible explanations include inadequate dosing, injection technique errors, or non-response.
• Your provider may recommend dose escalation, dietary counseling, or metabolic workup (thyroid function, cortisol, etc.).

If you are at week 16+ at maintenance dose (2.4 mg or equivalent compounded dose) and have lost less than 5% of body weight:

• Contact your provider. This meets the clinical definition of inadequate response. About 10% to 15% of patients do not achieve meaningful weight loss on semaglutide despite adequate dosing and adherence.
• Your provider may recommend switching to tirzepatide (which has higher average weight loss in head-to-head trials), adding behavioral therapy, or evaluating for underlying causes of weight-loss resistance.

If you experience severe side effects at any point (persistent vomiting, severe abdominal pain, signs of pancreatitis, allergic reaction):

• Contact your provider immediately or seek emergency care. Do not wait.

When semaglutide is NOT working: the 12-week rule

The clinical consensus, based on the STEP trial data and professional society guidelines, is that semaglutide should produce at least 5% body weight loss by week 12 to 16 at a therapeutic dose (1.0 mg or higher for most patients, 2.4 mg for maximum effect).

If you have not achieved 5% weight loss by week 16 at the 2.4 mg dose (or equivalent compounded dose), the medication is not working adequately. This is not treatment failure in the sense of doing something wrong. It is biological non-response.

The STEP 1 trial reported that 86% of participants achieved at least 5% weight loss by week 68. The inverse: 14% did not. Non-response is a real phenomenon, not a myth or an excuse.

Predictors of non-response include:

• Baseline BMI greater than 45 (higher BMI correlates with lower percentage weight loss, though absolute weight loss may still be substantial)
• Type 2 diabetes with significant insulin resistance
• Concurrent use of weight-promoting medications (antipsychotics, corticosteroids, insulin)
• Genetic polymorphisms in the GLP-1 receptor gene (rare but documented)
• Undiagnosed metabolic disorders (hypothyroidism, Cushing's syndrome, polycystic ovary syndrome)

If semaglutide is not working by the 12 to 16 week mark at therapeutic dose, the options are:

1. Switch to tirzepatide. Tirzepatide (Mounjaro, Zepbound, compounded versions) is a dual GLP-1/GIP agonist with higher average weight loss than semaglutide in head-to-head trials. The SURMOUNT-1 trial showed 20.9% weight loss at week 72 on tirzepatide 15 mg vs 14.9% on semaglutide 2.4 mg in STEP 1 (Jastreboff et al., NEJM 2022).

1. Add behavioral therapy. The STEP 3 trial showed that intensive behavioral therapy (weekly counseling, meal replacements, exercise prescription) added 1% to 2% additional weight loss vs medication alone (Wadden et al., JAMA 2021).

1. Evaluate for underlying causes. Thyroid function tests, cortisol levels, sleep study for obstructive sleep apnea, evaluation for binge eating disorder, medication review.

1. Accept modest response and focus on non-scale victories. Some patients lose less weight than the trial average but still achieve meaningful improvements in blood pressure, hemoglobin A1c, lipids, and quality of life. Weight loss is not the only valid outcome.

The 12-week rule is a clinical guideline, not a hard cutoff. Some patients are slow responders who eventually achieve good results. But waiting indefinitely without reassessment is not evidence-based practice.

The FormBlends Three-Phase Response Model

Based on patterns observed across patient titration journeys, we have identified a three-phase response model that predicts long-term outcomes better than single-timepoint assessments.

Phase 1: Receptor Adaptation (Weeks 1 to 4). Characterized by initial side effects (nausea, fatigue, injection site reactions) and early appetite changes. Weight loss is minimal and mostly water. Patients who discontinue treatment most often do so in this phase due to side effects. The key predictor of continuation is whether side effects improve by week 3 to 4.

Phase 2: Metabolic Transition (Weeks 4 to 12). Characterized by steady weight loss, stabilization of side effects, and dose escalation. This is the phase where the medication either demonstrates clear efficacy or fails to do so. Patients who achieve at least 3% to 5% weight loss by week 12 almost always go on to achieve 10%+ loss by week 68. Those who achieve less than 2% loss by week 12 rarely reach 10% even with continued treatment.

Phase 3: Sustained Response (Weeks 12 to 68+). Characterized by continued weight loss at a slower rate, eventual plateau, and maintenance. The primary challenge in this phase is not efficacy but adherence, cost, and managing the psychological shift from active weight loss to maintenance.

The model's clinical utility is in identifying patients who are in Phase 2 non-response early enough to adjust treatment rather than waiting until week 68 to conclude the medication did not work.

[Diagram suggestion: Three overlapping bell curves showing the distribution of patient experiences in each phase. Phase 1 shows high variability in side effects. Phase 2 shows bifurcation into responders and non-responders. Phase 3 shows plateau and maintenance. Annotate key decision points: "Reassess side effects week 3-4," "Evaluate weight loss week 12," "Transition to maintenance mindset week 20+."]

FAQ

How quickly does semaglutide start working for weight loss? Measurable weight loss typically begins at week 4 to 8. The median time to 5% body weight loss in clinical trials is 12 weeks. Appetite suppression starts earlier, usually within 4 to 7 days of the first injection.

How long does it take to see results from semaglutide? Most patients see noticeable appetite suppression within the first week and measurable weight loss (3% to 5% of body weight) by week 8 to 12. Maximum weight loss occurs at 60 to 68 weeks, with most of the loss happening in the first 20 to 30 weeks.

Does semaglutide work immediately? Semaglutide binds to GLP-1 receptors within hours of injection, but the clinical effects (appetite suppression, weight loss) take days to weeks to become noticeable. You will not feel or see results immediately after your first injection.

Why am I not losing weight on semaglutide after 4 weeks? Four weeks is early in the treatment timeline, especially if you are still at the 0.25 mg starting dose. Most patients do not see significant weight loss until week 8 to 12 at higher doses. Ensure you are following the titration schedule and tracking weight consistently.

How long does it take for semaglutide to suppress appetite? Most patients report reduced hunger and earlier satiety within 4 to 7 days of the first injection. Some feel effects within 24 to 48 hours, while others take 2 to 3 weeks. Individual variation is normal.

What is the average weight loss per week on semaglutide? In the STEP 1 trial, patients on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks, which equals approximately 0.22% of body weight per week, or roughly 0.5 to 1 pound per week for a 200-pound person. The rate is faster in the first 20 weeks and slower thereafter.

Does compounded semaglutide work as fast as Wegovy? Yes. Compounded semaglutide contains the same active ingredient as Wegovy and has the same pharmacokinetics. The timeline for appetite suppression and weight loss is identical. Compounded formulations are not FDA-approved and may contain additional ingredients, but the semaglutide component works the same way.

Can I speed up semaglutide's effects by increasing the dose faster? No. Rapid dose escalation increases side effects (nausea, vomiting, diarrhea) without improving weight loss. The standard titration schedule is designed to balance efficacy and tolerability. Skipping steps or escalating faster than recommended increases the risk of discontinuation due to side effects.

How do I know if semaglutide is working? Signs that semaglutide is working include reduced hunger between meals, feeling full after eating less food, decreased food cravings, and measurable weight loss starting at week 4 to 8. If you have completed 12 weeks at a therapeutic dose (1.0 mg or higher) and have not lost at least 3% to 5% of body weight, contact your provider.

What should I do if semaglutide stops working? If weight loss plateaus after 20 to 30 weeks, this is normal and does not mean the medication stopped working. It means you have reached a new metabolic equilibrium. If you regain weight while still on treatment, possible causes include dietary changes, medication non-adherence, or development of antibodies (rare). Contact your provider for evaluation.

How long does it take for semaglutide to reach steady state in the body? Semaglutide has a half-life of approximately 7 days. Steady-state blood levels are reached after 4 to 5 half-lives, or 4 to 5 weeks at a given dose. If you escalate doses every 4 weeks, you reach steady state at the maintenance dose around week 20.

Does semaglutide work faster for people with diabetes? No. Patients with type 2 diabetes typically lose less weight on semaglutide than patients without diabetes (9.6% vs 14.9% in the STEP trials). The timeline is similar, but the magnitude of weight loss is lower, likely due to baseline insulin resistance and metabolic differences.

Sources

1. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Diabetes Care. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Pharmacology and Experimental Therapeutics. 2015.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4 trial). JAMA. 2021.
5. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obesity and Metabolism. 2018.
6. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 trial). Lancet. 2021.
7. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 trial). JAMA. 2021.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.
10. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes trial). New England Journal of Medicine. 2015.
12. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6 trial). New England Journal of Medicine. 2016.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Smits MM et al. GLP-1 based therapies: clinical implications for gastric emptying. Diabetes Obesity and Metabolism. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Tums, Rolaids, and Maalox are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.